Vyne Therapeutics Inc (VYNE NASDAQ) stock market data APIs
$3.06
0.31(11.3%)
as of January 14, 2025
Vyne Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Prev. Close
2.75
Open
3.06
Volume
102 K
High
3.1
Low
2.68
52 wk Range
1.57-4.3
Market Cap
44 254 K
P/E Ratio
1.7442
Shares Outstanding
14 749 K
Revenue
486 K
EPS
-0.29
Beta
1.354
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Vyne Therapeutics Inc data using free add-ons & libraries
Get Vyne Therapeutics Inc Fundamental Data
Vyne Therapeutics Inc Fundamental data includes:
- Net Revenue: 486 K
- EBITDA: -29 186 000
- Earnings Per Share: 1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-11
- EPS/Forecast: -0.23
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Vyne Therapeutics Inc News
New
15 Best Acne Treatment Products For Teens in 2024
In this article, we will be taking a look at the 15 best acne treatment products for teens in 2024. If you are not interested in reading about the teen tailored skin innovations in detail, head straig...
VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
Transformative capital raise of $88.2 million from leading healthcare investors provides funding for BET inhibitor programs through the end of 2025 Phase 2b preparatory activities progressing for VYN...
VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023
Event will highlight VYN201 Phase 1b trial results, VYN202 preclinical data and VYNE’s clinical development plans Program to feature KOL presentation covering unmet need and current treatment lands...
VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million
BRIDGEWATER, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innov...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
